ID   VGFR1_HUMAN             Reviewed;        1338 AA.
AC   P17948; A3E342; A3E344; A8KA71; B0LPF1; B2BF46; B2BF47; B2BF48;
AC   B3FR89; B5A923; F5H5L6; O60722; P16057; Q12954;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   10-MAY-2017, entry version 207.
DE   RecName: Full=Vascular endothelial growth factor receptor 1;
DE            Short=VEGFR-1;
DE            EC=2.7.10.1;
DE   AltName: Full=Fms-like tyrosine kinase 1;
DE            Short=FLT-1;
DE   AltName: Full=Tyrosine-protein kinase FRT;
DE   AltName: Full=Tyrosine-protein kinase receptor FLT;
DE            Short=FLT;
DE   AltName: Full=Vascular permeability factor receptor;
DE   Flags: Precursor;
GN   Name=FLT1; Synonyms=FLT, FRT, VEGFR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2158038;
RA   Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H.,
RA   Sato M.;
RT   "Nucleotide sequence and expression of a novel human receptor-type
RT   tyrosine kinase gene (flt) closely related to the fms family.";
RL   Oncogene 5:519-524(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PROTEIN SEQUENCE OF
RP   N-TERMINUS, SUBCELLULAR LOCATION (ISOFORM 2), INTERACTION WITH VEGFA,
RP   AND FUNCTION.
RC   TISSUE=Umbilical vein;
RX   PubMed=8248162; DOI=10.1073/pnas.90.22.10705;
RA   Kendall R.L., Thomas K.A.;
RT   "Inhibition of vascular endothelial cell growth factor activity by an
RT   endogenously encoded soluble receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10705-10709(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH VEGFA, AND
RP   GLYCOSYLATION.
RC   TISSUE=Umbilical vein;
RX   PubMed=10471394; DOI=10.1006/bbrc.1999.1282;
RA   Herley M.T., Yu Y., Whitney R.G., Sato J.D.;
RT   "Characterization of the VEGF binding site on the Flt-1 receptor.";
RL   Biochem. Biophys. Res. Commun. 262:731-738(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION IN LIGAND BINDING,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, ROLE IN PREECLAMPSIA, AND INDUCTION.
RX   PubMed=18515749; DOI=10.1161/CIRCRESAHA.108.171504;
RA   Sela S., Itin A., Natanson-Yaron S., Greenfield C., Goldman-Wohl D.,
RA   Yagel S., Keshet E.;
RT   "A novel human-specific soluble vascular endothelial growth factor
RT   receptor 1: cell-type-specific splicing and implications to vascular
RT   endothelial growth factor homeostasis and preeclampsia.";
RL   Circ. Res. 102:1566-1574(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 6; 7 AND 8), ALTERNATIVE
RP   SPLICING, FUNCTION IN PHOSPHORYLATION OF SRC AND CANCER CELL
RP   INVASIVENESS, AND TISSUE SPECIFICITY.
RX   PubMed=20512933; DOI=10.1002/jcb.22584;
RA   Mezquita B., Mezquita J., Pau M., Mezquita C.;
RT   "A novel intracellular isoform of VEGFR-1 activates Src and promotes
RT   cell invasion in MDA-MB-231 breast cancer cells.";
RL   J. Cell. Biochem. 110:732-742(2010).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Mezquita J., Mezquita B., Pau M., Mezquita C.;
RT   "A new VEGFR1 receptor transcript coding for the extracellular domains
RT   of the protein followed by a C-terminal polyserine tail.";
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Placenta, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1018-1058, AND ALTERNATIVE
RP   SPLICING (ISOFORM 1).
RX   PubMed=3040650;
RA   Matsushime H., Yoshida M.C., Sasaki M., Shibuya M.;
RT   "A possible new member of tyrosine kinase family, human frt sequence,
RT   is highly conserved in vertebrates and located on human chromosome
RT   13.";
RL   Jpn. J. Cancer Res. 78:655-661(1987).
RN   [14]
RP   PARTIAL PROTEIN SEQUENCE, CATALYTIC ACTIVITY, PHOSPHORYLATION AT
RP   TYR-914; TYR-1213; TYR-1242; TYR-1327 AND TYR-1333, MUTAGENESIS OF
RP   TYR-914; TYR-1213; TYR-1242; TYR-1327 AND TYR-1333, AND INTERACTION
RP   WITH PLCG; GRB2; CRK; NCK1 AND PTPN11.
RX   PubMed=9722576; DOI=10.1074/jbc.273.36.23410;
RA   Ito N., Wernstedt C., Engstrom U., Claesson-Welsh L.;
RT   "Identification of vascular endothelial growth factor receptor-1
RT   tyrosine phosphorylation sites and binding of SH2 domain-containing
RT   molecules.";
RL   J. Biol. Chem. 273:23410-23418(1998).
RN   [15]
RP   INTERACTION WITH VEGFA, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY,
RP   FUNCTION IN PHOSPHORYLATION OF PLCG, AND ABSENCE OF MITOGENIC FUNCTION
RP   IN CULTURED FIBROBLASTS.
RX   PubMed=7824266;
RA   Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M.;
RT   "A unique signal transduction from FLT tyrosine kinase, a receptor for
RT   vascular endothelial growth factor VEGF.";
RL   Oncogene 10:135-147(1995).
RN   [16]
RP   FUNCTION IN CELL MIGRATION, FUNCTION IN VEGFA AND PGF SIGNALING, AND
RP   INDUCTION.
RX   PubMed=8605350;
RA   Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D.;
RT   "Migration of human monocytes in response to vascular endothelial
RT   growth factor (VEGF) is mediated via the VEGF receptor flt-1.";
RL   Blood 87:3336-3343(1996).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG AND ACTIVATION OF MAP KINASES,
RP   INTERACTION WITH PLCG, CATALYTIC ACTIVITY, MUTAGENESIS OF LYS-861 AND
RP   TYR-1169, AND PHOSPHORYLATION AT TYR-1169 AND TYR-1213.
RX   PubMed=9299537; DOI=10.1006/bbrc.1997.7327;
RA   Sawano A., Takahashi T., Yamaguchi S., Shibuya M.;
RT   "The phosphorylated 1169-tyrosine containing region of flt-1 kinase
RT   (VEGFR-1) is a major binding site for PLCgamma.";
RL   Biochem. Biophys. Res. Commun. 238:487-491(1997).
RN   [18]
RP   INTERACTION WITH PIK3R1; PTPN11 AND NCK1, AND PHOSPHORYLATION AT
RP   TYR-1213.
RX   PubMed=9600074; DOI=10.1006/bbrc.1998.8578;
RA   Igarashi K., Isohara T., Kato T., Shigeta K., Yamano T., Uno I.;
RT   "Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2.";
RL   Biochem. Biophys. Res. Commun. 246:95-99(1998).
RN   [19]
RP   FUNCTION AS NEGATIVE REGULATOR OF KDR-MEDIATED CELL PROLIFERATION.
RX   PubMed=11141500; DOI=10.1016/S0002-9440(10)63965-X;
RA   Dunk C., Ahmed A.;
RT   "Vascular endothelial growth factor receptor-2-mediated mitogenesis is
RT   negatively regulated by vascular endothelial growth factor receptor-1
RT   in tumor epithelial cells.";
RL   Am. J. Pathol. 158:265-273(2001).
RN   [20]
RP   INTERACTION WITH PIK3R1 AND VEGFA, AUTOPHOSPHORYLATION,
RP   PHOSPHORYLATION AT TYR-1213, SUBCELLULAR LOCATION, IDENTIFICATION BY
RP   MASS SPECTROMETRY, AND GLYCOSYLATION.
RX   PubMed=11513746; DOI=10.1042/0264-6021:3580465;
RA   Yu Y., Hulmes J.D., Herley M.T., Whitney R.G., Crabb J.W., Sato J.D.;
RT   "Direct identification of a major autophosphorylation site on vascular
RT   endothelial growth factor receptor Flt-1 that mediates
RT   phosphatidylinositol 3'-kinase binding.";
RL   Biochem. J. 358:465-472(2001).
RN   [21]
RP   FUNCTION IN PGF-MEDIATED CHORIOCARCINOMA CELL PROLIFERATION.
RX   PubMed=11811792; DOI=10.3109/08977190109001086;
RA   Angelucci C., Lama G., Iacopino F., Maglione D., Sica G.;
RT   "Effect of placenta growth factor-1 on proliferation and release of
RT   nitric oxide, cyclic AMP and cyclic GMP in human epithelial cells
RT   expressing the FLT-1 receptor.";
RL   Growth Factors 19:193-206(2001).
RN   [22]
RP   INTERACTION WITH KDR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND
RP   FUNCTION IN VEGFA SIGNALING; PHOSPHORYLATION OF PLCG AND ACTIVATION OF
RP   PHOSPHATIDYLINOSITOL KINASE AND PHOSPHOLIPASE C.
RX   PubMed=11312102; DOI=10.1016/S1357-2725(01)00019-X;
RA   Huang K., Andersson C., Roomans G.M., Ito N., Claesson-Welsh L.;
RT   "Signaling properties of VEGF receptor-1 and -2 homo- and
RT   heterodimers.";
RL   Int. J. Biochem. Cell Biol. 33:315-324(2001).
RN   [23]
RP   FUNCTION IN SIGNALING VIA ACTIVATION OF THE PHOSPHATIDYLINOSITOL
RP   KINASE PATHWAY AND POSITIVE REGULATION OF ANGIOGENESIS IN RESPONSE TO
RP   PGF AND VEGFA.
RX   PubMed=14633857; DOI=10.2337/diabetes.52.12.2959;
RA   Cai J., Ahmad S., Jiang W.G., Huang J., Kontos C.D., Boulton M.,
RA   Ahmed A.;
RT   "Activation of vascular endothelial growth factor receptor-1 sustains
RT   angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-
RT   kinase pathway in endothelial cells.";
RL   Diabetes 52:2959-2968(2003).
RN   [24]
RP   INTERACTION WITH PGF AND KDR, FUNCTION IN PHOSPHORYLATION OF KDR;
RP   VEGFA AND PGF SIGNALING, CATALYTIC ACTIVITY, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND PHOSPHORYLATION AT TYR-1213; TYR-1327 AND TYR-1309.
RX   PubMed=12796773; DOI=10.1038/nm884;
RA   Autiero M., Waltenberger J., Communi D., Kranz A., Moons L.,
RA   Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S.,
RA   Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U.,
RA   Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P.,
RA   Dehio C., Hicklin D.J., Persico G., Herbert J.M., Communi D.,
RA   Shibuya M., Collen D., Conway E.M., Carmeliet P.;
RT   "Role of PlGF in the intra- and intermolecular cross talk between the
RT   VEGF receptors Flt1 and Flk1.";
RL   Nat. Med. 9:936-943(2003).
RN   [25]
RP   INTERACTION WITH CBL AND CD2AP, UBIQUITINATION, AUTOPHOSPHORYLATION IN
RP   RESPONSE TO VEGFA, MUTAGENESIS OF TYR-1333, AND SUBCELLULAR LOCATION.
RX   PubMed=15001553; DOI=10.1096/fj.03-0767fje;
RA   Kobayashi S., Sawano A., Nojima Y., Shibuya M., Maru Y.;
RT   "The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and
RT   degradation of Flt-1 (VEGFR-1).";
RL   FASEB J. 18:929-931(2004).
RN   [26]
RP   FUNCTION IN VEGFA AND VEGFB SIGNALING; CANCER CELL MIGRATION;
RP   INVASIVENESS AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1.
RX   PubMed=15735759; DOI=10.1038/sj.onc.1208246;
RA   Fan F., Wey J.S., McCarty M.F., Belcheva A., Liu W., Bauer T.W.,
RA   Somcio R.J., Wu Y., Hooper A., Hicklin D.J., Ellis L.M.;
RT   "Expression and function of vascular endothelial growth factor
RT   receptor-1 on human colorectal cancer cells.";
RL   Oncogene 24:2647-2653(2005).
RN   [27]
RP   FUNCTION IN CELL MIGRATION AND PHOSPHORYLATION OF PTK2/FAK1; YES1 AND
RP   SRC.
RX   PubMed=16685275; DOI=10.1038/sj.bjc.6603143;
RA   Lesslie D.P., Summy J.M., Parikh N.U., Fan F., Trevino J.G.,
RA   Sawyer T.K., Metcalf C.A., Shakespeare W.C., Hicklin D.J., Ellis L.M.,
RA   Gallick G.E.;
RT   "Vascular endothelial growth factor receptor-1 mediates migration of
RT   human colorectal carcinoma cells by activation of Src family
RT   kinases.";
RL   Br. J. Cancer 94:1710-1717(2006).
RN   [28]
RP   MUTAGENESIS OF ASN-1050.
RX   PubMed=16286478; DOI=10.1074/jbc.M506454200;
RA   Meyer R.D., Mohammadi M., Rahimi N.;
RT   "A single amino acid substitution in the activation loop defines the
RT   decoy characteristic of VEGFR-1/FLT-1.";
RL   J. Biol. Chem. 281:867-875(2006).
RN   [29]
RP   FUNCTION IN PGF AND VEGFA SIGNALING; PHOSPHORYLATION OF AKT1;
RP   MAPK3/ERK1 AND MAP KINASES; CHEMOTAXIS AND ACTIVATION OF
RP   PHOSPHATIDYLINOSITOL 3-KINASE, AND AUTOPHOSPHORYLATION IN RESPONSE TO
RP   PGF AND VEGFA.
RX   PubMed=18079407; DOI=10.1161/ATVBAHA.107.158022;
RA   Tchaikovski V., Fellbrich G., Waltenberger J.;
RT   "The molecular basis of VEGFR-1 signal transduction pathways in
RT   primary human monocytes.";
RL   Arterioscler. Thromb. Vasc. Biol. 28:322-328(2008).
RN   [30]
RP   FUNCTION IN ENDOTHELIAL CELL SURVIVAL AND ANGIOGENESIS.
RX   PubMed=18583712; DOI=10.1161/CIRCRESAHA.108.174128;
RA   Nishi J., Minamino T., Miyauchi H., Nojima A., Tateno K., Okada S.,
RA   Orimo M., Moriya J., Fong G.H., Sunagawa K., Shibuya M., Komuro I.;
RT   "Vascular endothelial growth factor receptor-1 regulates postnatal
RT   angiogenesis through inhibition of the excessive activation of Akt.";
RL   Circ. Res. 103:261-268(2008).
RN   [31]
RP   FUNCTION IN CANCER CELL MIGRATION AND ACTIVATION OF MAPK1/ERK2 AND/OR
RP   MAPK3/ERK1.
RX   PubMed=20551949; DOI=10.1038/sj.bjc.6605746;
RA   Taylor A.P., Leon E., Goldenberg D.M.;
RT   "Placental growth factor (PlGF) enhances breast cancer cell motility
RT   by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement.";
RL   Br. J. Cancer 103:82-89(2010).
RN   [32]
RP   INTERACTION WITH RACK1.
RX   PubMed=21212275; DOI=10.1074/jbc.M110.165605;
RA   Wang F., Yamauchi M., Muramatsu M., Osawa T., Tsuchida R., Shibuya M.;
RT   "RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a
RT   PI3-K/Akt pathway.";
RL   J. Biol. Chem. 286:9097-9106(2011).
RN   [33]
RP   INTERACTION WITH PSEN1 AND PTPRB, DEPHOSPHORYLATION BY PTPRB,
RP   MUTAGENESIS OF VAL-767, AND PROTEOLYTIC CLEAVAGE BY PSEN1 AT VAL-767.
RX   PubMed=22016384; DOI=10.1074/jbc.M111.296590;
RA   Cai J., Chen Z., Ruan Q., Han S., Liu L., Qi X., Boye S.L.,
RA   Hauswirth W.W., Grant M.B., Boulton M.E.;
RT   "gamma-Secretase and presenilin mediate cleavage and phosphorylation
RT   of vascular endothelial growth factor receptor-1.";
RL   J. Biol. Chem. 286:42514-42523(2011).
RN   [34]
RP   FUNCTION AS DECOY RECEPTORS; REGULATION OF VEGFA SIGNALING AND
RP   REGULATION OF KDR ACTIVITY (ISOFORMS 2/3/4), AND ROLE IN PREECLAMPSIA.
RX   PubMed=21752276; DOI=10.1186/2045-824X-3-15;
RA   Ahmad S., Hewett P.W., Al-Ani B., Sissaoui S., Fujisawa T.,
RA   Cudmore M.J., Ahmed A.;
RT   "Autocrine activity of soluble Flt-1 controls endothelial cell
RT   function and angiogenesis.";
RL   Vasc. Cell 3:15-15(2011).
RN   [35]
RP   REVIEW ON FUNCTION AS NEGATIVE REGULATOR OF ANGIOGENESIS DURING
RP   EMBRYONIC DEVELOPMENT; POSITIVE REGULATION OF MACROPHAGE FUNCTION IN
RP   ADULTHOOD; ROLE IN CARCINOGENESIS AND INFLAMMATION.
RX   PubMed=17002866; DOI=10.5483/BMBRep.2006.39.5.469;
RA   Shibuya M.;
RT   "Differential roles of vascular endothelial growth factor receptor-1
RT   and receptor-2 in angiogenesis.";
RL   J. Biochem. Mol. Biol. 39:469-478(2006).
RN   [36]
RP   REVIEW ON STRUCTURE AND FUNCTION.
RX   PubMed=18680722; DOI=10.1016/j.bbrc.2008.07.121;
RA   Roskoski R. Jr.;
RT   "VEGF receptor protein-tyrosine kinases: structure and regulation.";
RL   Biochem. Biophys. Res. Commun. 375:287-291(2008).
RN   [37]
RP   REVIEW ON ROLE IN ANGIOGENESIS AND CANCER.
RX   PubMed=19230644; DOI=10.1016/j.ceb.2008.12.012;
RA   Lohela M., Bry M., Tammela T., Alitalo K.;
RT   "VEGFs and receptors involved in angiogenesis versus
RT   lymphangiogenesis.";
RL   Curr. Opin. Cell Biol. 21:154-165(2009).
RN   [38]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=19761875; DOI=10.1016/j.bbapap.2009.09.002;
RA   Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K.;
RT   "Structure-function analysis of VEGF receptor activation and the role
RT   of coreceptors in angiogenic signaling.";
RL   Biochim. Biophys. Acta 1804:567-580(2010).
RN   [39]
RP   REVIEW ON ROLE IN CANCER.
RX   PubMed=20127948; DOI=10.1002/cncr.24789;
RA   Schwartz J.D., Rowinsky E.K., Youssoufian H., Pytowski B., Wu Y.;
RT   "Vascular endothelial growth factor receptor-1 in human cancer:
RT   concise review and rationale for development of IMC-18F1 (Human
RT   antibody targeting vascular endothelial growth factor receptor-1).";
RL   Cancer 116:1027-1032(2010).
RN   [40]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=21711246; DOI=10.1042/BJ20110301;
RA   Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L.;
RT   "Signal transduction by vascular endothelial growth factor
RT   receptors.";
RL   Biochem. J. 437:169-183(2011).
RN   [41]
RP   REVIEW ON ROLE IN CANCER AND PREECLAMPSIA.
RX   PubMed=21558755; DOI=10.2183/pjab.87.167;
RA   Shibuya M.;
RT   "Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia.";
RL   Proc. Jpn. Acad., B, Phys. Biol. Sci. 87:167-178(2011).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 132-226 IN COMPLEX WITH
RP   VEGFA, AND DOMAIN.
RX   PubMed=9393862; DOI=10.1016/S0092-8674(00)80456-0;
RA   Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A.,
RA   de Vos A.M.;
RT   "Crystal structure at 1.7 A resolution of VEGF in complex with domain
RT   2 of the Flt-1 receptor.";
RL   Cell 91:695-704(1997).
RN   [43]
RP   STRUCTURE BY NMR OF 129-229, X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF
RP   129-229 IN COMPLEX WITH VEGFA, SUBUNIT, AND INTERACTION WITH VEGFA.
RX   PubMed=10543948; DOI=10.1006/jmbi.1999.3134;
RA   Starovasnik M.A., Christinger H.W., Wiesmann C., Champe M.A.,
RA   de Vos A.M., Skelton N.J.;
RT   "Solution structure of the VEGF-binding domain of Flt-1: comparison of
RT   its free and bound states.";
RL   J. Mol. Biol. 293:531-544(1999).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 130-229 IN COMPLEX WITH PGF.
RX   PubMed=14684734; DOI=10.1074/jbc.M313237200;
RA   Christinger H.W., Fuh G., de Vos A.M., Wiesmann C.;
RT   "The crystal structure of placental growth factor in complex with
RT   domain 2 of vascular endothelial growth factor receptor-1.";
RL   J. Biol. Chem. 279:10382-10388(2004).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF 129-226 IN COMPLEX WITH
RP   VEGFB, INTERACTION WITH VEGFB, SUBUNIT, AND DOMAIN.
RX   PubMed=20501651; DOI=10.1074/jbc.M110.130658;
RA   Iyer S., Darley P.I., Acharya K.R.;
RT   "Structural insights into the binding of vascular endothelial growth
RT   factor-B by VEGFR-1(D2): recognition and specificity.";
RL   J. Biol. Chem. 285:23779-23789(2010).
RN   [46]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-60; LYS-144; GLN-281; ILE-422;
RP   GLN-781; VAL-938; ALA-982 AND VAL-1061.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface
CC       receptor for VEGFA, VEGFB and PGF, and plays an essential role in
CC       the development of embryonic vasculature, the regulation of
CC       angiogenesis, cell survival, cell migration, macrophage function,
CC       chemotaxis, and cancer cell invasion. May play an essential role
CC       as a negative regulator of embryonic angiogenesis by inhibiting
CC       excessive proliferation of endothelial cells. Can promote
CC       endothelial cell proliferation, survival and angiogenesis in
CC       adulthood. Its function in promoting cell proliferation seems to
CC       be cell-type specific. Promotes PGF-mediated proliferation of
CC       endothelial cells, proliferation of some types of cancer cells,
CC       but does not promote proliferation of normal fibroblasts (in
CC       vitro). Has very high affinity for VEGFA and relatively low
CC       protein kinase activity; may function as a negative regulator of
CC       VEGFA signaling by limiting the amount of free VEGFA and
CC       preventing its binding to KDR. Likewise, isoforms lacking a
CC       transmembrane domain, such as isoform 2, isoform 3 and isoform 4,
CC       may function as decoy receptors for VEGFA. Modulates KDR signaling
CC       by forming heterodimers with KDR. Ligand binding leads to the
CC       activation of several signaling cascades. Activation of PLCG leads
CC       to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate and the activation
CC       of protein kinase C. Mediates phosphorylation of PIK3R1, the
CC       regulatory subunit of phosphatidylinositol 3-kinase, leading to
CC       activation of phosphatidylinositol kinase and the downstream
CC       signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1
CC       and the MAP kinase signaling pathway, as well as of the AKT1
CC       signaling pathway. Phosphorylates SRC and YES1, and may also
CC       phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes
CC       phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of
CC       PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases
CC       phosphorylation of SRC at 'Tyr-418' by unknown means and promotes
CC       tumor cell invasion. {ECO:0000269|PubMed:11141500,
CC       ECO:0000269|PubMed:11312102, ECO:0000269|PubMed:11811792,
CC       ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:14633857,
CC       ECO:0000269|PubMed:15735759, ECO:0000269|PubMed:16685275,
CC       ECO:0000269|PubMed:18079407, ECO:0000269|PubMed:18515749,
CC       ECO:0000269|PubMed:18583712, ECO:0000269|PubMed:18593464,
CC       ECO:0000269|PubMed:20512933, ECO:0000269|PubMed:20551949,
CC       ECO:0000269|PubMed:21752276, ECO:0000269|PubMed:7824266,
CC       ECO:0000269|PubMed:8248162, ECO:0000269|PubMed:8605350,
CC       ECO:0000269|PubMed:9299537}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11312102,
CC       ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:7824266,
CC       ECO:0000269|PubMed:9299537, ECO:0000269|PubMed:9722576}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of VEGFA, VEGFB or PGF leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues.
CC   -!- SUBUNIT: Interacts with VEGFA, VEGFB and PGF. Monomer in the
CC       absence of bound VEGFA, VEGFB or PGF. Homodimer in the presence of
CC       bound VEGFA, VEGFB and PGF. Can also form a heterodimer with KDR.
CC       Interacts (when tyrosine phosphorylated) with CBL, CRK, GRB2,
CC       NCK1, PIK3R1, PLCG, PSEN1 and PTPN11. Probably interacts also with
CC       PTPRB. Interacts with RACK1. Identified in a complex with CBL and
CC       CD2AP. {ECO:0000269|PubMed:10471394, ECO:0000269|PubMed:10543948,
CC       ECO:0000269|PubMed:11312102, ECO:0000269|PubMed:11513746,
CC       ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:14684734,
CC       ECO:0000269|PubMed:15001553, ECO:0000269|PubMed:20501651,
CC       ECO:0000269|PubMed:21212275, ECO:0000269|PubMed:22016384,
CC       ECO:0000269|PubMed:7824266, ECO:0000269|PubMed:8248162,
CC       ECO:0000269|PubMed:9299537, ECO:0000269|PubMed:9393862,
CC       ECO:0000269|PubMed:9600074, ECO:0000269|PubMed:9722576}.
CC   -!- INTERACTION:
CC       P22681:CBL; NbExp=2; IntAct=EBI-1026718, EBI-518228;
CC       P46109:CRKL; NbExp=9; IntAct=EBI-1026718, EBI-910;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-1026718, EBI-491549;
CC       P08631:HCK; NbExp=2; IntAct=EBI-1026718, EBI-346340;
CC       P98160:HSPG2; NbExp=2; IntAct=EBI-6530464, EBI-6896259;
CC       P49763:PGF; NbExp=2; IntAct=EBI-1026718, EBI-1037633;
CC       P27986:PIK3R1; NbExp=2; IntAct=EBI-1026718, EBI-79464;
CC       P19174:PLCG1; NbExp=2; IntAct=EBI-1026718, EBI-79387;
CC       Q05397:PTK2; NbExp=2; IntAct=EBI-1026718, EBI-702142;
CC       Q06124:PTPN11; NbExp=2; IntAct=EBI-1026718, EBI-297779;
CC       Q12913:PTPRJ; NbExp=2; IntAct=EBI-1026718, EBI-2264500;
CC       P15692:VEGFA; NbExp=4; IntAct=EBI-1026718, EBI-1026643;
CC       P15692-4:VEGFA; NbExp=3; IntAct=EBI-1026718, EBI-1026691;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Endosome. Note=Autophosphorylation promotes
CC       ubiquitination and endocytosis.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted
CC       {ECO:0000269|PubMed:8248162}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Cytoplasm {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 6: Cytoplasm {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 7: Cytoplasm {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=Flt1;
CC         IsoId=P17948-1; Sequence=Displayed;
CC       Name=2; Synonyms=sFlt1;
CC         IsoId=P17948-2; Sequence=VSP_002955, VSP_002956;
CC       Name=3; Synonyms=sFlt1-14;
CC         IsoId=P17948-3; Sequence=VSP_041927, VSP_041928;
CC       Name=4;
CC         IsoId=P17948-4; Sequence=VSP_041929, VSP_041930;
CC       Name=5; Synonyms=i15;
CC         IsoId=P17948-5; Sequence=VSP_041985;
CC       Name=6; Synonyms=i18;
CC         IsoId=P17948-6; Sequence=VSP_041984;
CC       Name=7; Synonyms=i21;
CC         IsoId=P17948-7; Sequence=VSP_041983;
CC       Name=8;
CC         IsoId=P17948-8; Sequence=VSP_047759, VSP_047760;
CC   -!- TISSUE SPECIFICITY: Detected in normal lung, but also in placenta,
CC       liver, kidney, heart and brain tissues. Specifically expressed in
CC       most of the vascular endothelial cells, and also expressed in
CC       peripheral blood monocytes. Isoform 2 is strongly expressed in
CC       placenta. Isoform 3 is expressed in corneal epithelial cells (at
CC       protein level). Isoform 3 is expressed in vascular smooth muscle
CC       cells (VSMC). {ECO:0000269|PubMed:18515749,
CC       ECO:0000269|PubMed:20512933}.
CC   -!- INDUCTION: Up-regulated in coculture of VSMC/endothelial cell (EC)
CC       or by direct exposure to VEGF of VSMC monoculture. Up-regulated
CC       from the second trimester of pregnancy to the term and in the
CC       placenta of women with preeclampsia (PE). Up-regulated in
CC       monocytes exposed to bacterial lipopolysaccharide (LPS).
CC       {ECO:0000269|PubMed:18515749, ECO:0000269|PubMed:8605350}.
CC   -!- DOMAIN: The second and third Ig-like C2-type (immunoglobulin-like)
CC       domains are sufficient for VEGFA binding.
CC       {ECO:0000269|PubMed:20501651, ECO:0000269|PubMed:9393862}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:10471394,
CC       ECO:0000269|PubMed:11513746}.
CC   -!- PTM: Ubiquitinated after VEGFA-mediated autophosphorylation,
CC       leading to proteolytic degradation. {ECO:0000269|PubMed:15001553}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-1169 is important for interaction
CC       with PLCG. Phosphorylation at Tyr-1213 is important for
CC       interaction with PIK3R1, PTPN11, GRB2, and PLCG. Phosphorylation
CC       at Tyr-1333 is important for endocytosis and for interaction with
CC       CBL, NCK1 and CRK. Is probably dephosphorylated by PTPRB.
CC       {ECO:0000269|PubMed:11513746, ECO:0000269|PubMed:12796773,
CC       ECO:0000269|PubMed:9299537, ECO:0000269|PubMed:9600074,
CC       ECO:0000269|PubMed:9722576}.
CC   -!- DISEASE: Note=Can contribute to cancer cell survival,
CC       proliferation, migration, and invasion, and tumor angiogenesis and
CC       metastasis. May contribute to cancer pathogenesis by promoting
CC       inflammatory responses and recruitment of tumor-infiltrating
CC       macrophages.
CC   -!- DISEASE: Note=Abnormally high expression of soluble isoforms
CC       (isoform 2, isoform 3 or isoform 4) may be a cause of
CC       preeclampsia.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X51602; CAA35946.1; -; mRNA.
DR   EMBL; U01134; AAC50060.1; -; mRNA.
DR   EMBL; AF063657; AAC16449.2; -; mRNA.
DR   EMBL; EU826561; ACF47597.1; -; mRNA.
DR   EMBL; EU368830; ACA62948.1; -; mRNA.
DR   EMBL; DQ836394; ABI53803.1; -; mRNA.
DR   EMBL; DQ836395; ABI53804.1; -; mRNA.
DR   EMBL; DQ836396; ABI53805.1; -; mRNA.
DR   EMBL; EF491868; ABS32268.1; -; mRNA.
DR   EMBL; EF491869; ABS32269.1; -; mRNA.
DR   EMBL; EF491870; ABS32270.1; -; mRNA.
DR   EMBL; EU360600; ACB05747.1; -; mRNA.
DR   EMBL; EU332841; ABY87530.1; -; Genomic_DNA.
DR   EMBL; AK292936; BAF85625.1; -; mRNA.
DR   EMBL; AK300392; BAG62125.1; -; mRNA.
DR   EMBL; AL138712; CAI14846.1; -; Genomic_DNA.
DR   EMBL; AL139005; CAI14846.1; JOINED; Genomic_DNA.
DR   EMBL; AL139005; CAI17096.1; -; Genomic_DNA.
DR   EMBL; AL138712; CAI17096.1; JOINED; Genomic_DNA.
DR   EMBL; CH471075; EAX08431.1; -; Genomic_DNA.
DR   EMBL; CH471075; EAX08432.1; -; Genomic_DNA.
DR   EMBL; BC039007; AAH39007.1; -; mRNA.
DR   EMBL; D00133; BAA00080.1; -; Genomic_DNA.
DR   CCDS; CCDS53860.1; -. [P17948-3]
DR   CCDS; CCDS53861.1; -. [P17948-4]
DR   CCDS; CCDS73556.1; -. [P17948-2]
DR   CCDS; CCDS9330.1; -. [P17948-1]
DR   PIR; A49636; A49636.
DR   PIR; S09982; S09982.
DR   RefSeq; NP_001153392.1; NM_001159920.1. [P17948-2]
DR   RefSeq; NP_001153502.1; NM_001160030.1. [P17948-3]
DR   RefSeq; NP_001153503.1; NM_001160031.1. [P17948-4]
DR   RefSeq; NP_002010.2; NM_002019.4. [P17948-1]
DR   UniGene; Hs.594454; -.
DR   PDB; 1FLT; X-ray; 1.70 A; X/Y=132-226.
DR   PDB; 1QSV; NMR; -; A=129-229.
DR   PDB; 1QSZ; NMR; -; A=129-229.
DR   PDB; 1QTY; X-ray; 2.70 A; T/U/X/Y=129-229.
DR   PDB; 1RV6; X-ray; 2.45 A; X/Y=130-229.
DR   PDB; 2XAC; X-ray; 2.71 A; C/X=129-226.
DR   PDB; 3HNG; X-ray; 2.70 A; A=801-1158.
DR   PDB; 4CKV; X-ray; 2.06 A; X=132-225.
DR   PDB; 4CL7; X-ray; 2.00 A; A/B/C/D=132-225.
DR   PDB; 5ABD; X-ray; 2.00 A; E/I/X=132-226.
DR   PDB; 5EX3; X-ray; 2.41 A; D=827-835.
DR   PDB; 5T89; X-ray; 4.00 A; X/Y=27-656.
DR   PDBsum; 1FLT; -.
DR   PDBsum; 1QSV; -.
DR   PDBsum; 1QSZ; -.
DR   PDBsum; 1QTY; -.
DR   PDBsum; 1RV6; -.
DR   PDBsum; 2XAC; -.
DR   PDBsum; 3HNG; -.
DR   PDBsum; 4CKV; -.
DR   PDBsum; 4CL7; -.
DR   PDBsum; 5ABD; -.
DR   PDBsum; 5EX3; -.
DR   PDBsum; 5T89; -.
DR   ProteinModelPortal; P17948; -.
DR   SMR; P17948; -.
DR   BioGrid; 108609; 14.
DR   DIP; DIP-643N; -.
DR   IntAct; P17948; 30.
DR   MINT; MINT-127610; -.
DR   STRING; 9606.ENSP00000282397; -.
DR   BindingDB; P17948; -.
DR   ChEMBL; CHEMBL1868; -.
DR   DrugBank; DB06080; ABT-869.
DR   DrugBank; DB06626; Axitinib.
DR   DrugBank; DB06101; IMC-1C11.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB07288; N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB05913; OSI-930.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05075; TG100801.
DR   DrugBank; DB04879; Vatalanib.
DR   GuidetoPHARMACOLOGY; 1812; -.
DR   iPTMnet; P17948; -.
DR   PhosphoSitePlus; P17948; -.
DR   UniCarbKB; P17948; -.
DR   BioMuta; FLT1; -.
DR   DMDM; 143811474; -.
DR   EPD; P17948; -.
DR   MaxQB; P17948; -.
DR   PaxDb; P17948; -.
DR   PeptideAtlas; P17948; -.
DR   PRIDE; P17948; -.
DR   DNASU; 2321; -.
DR   Ensembl; ENST00000282397; ENSP00000282397; ENSG00000102755. [P17948-1]
DR   Ensembl; ENST00000539099; ENSP00000442630; ENSG00000102755. [P17948-4]
DR   Ensembl; ENST00000541932; ENSP00000437631; ENSG00000102755. [P17948-3]
DR   Ensembl; ENST00000543394; ENSP00000437841; ENSG00000102755. [P17948-8]
DR   Ensembl; ENST00000615840; ENSP00000484039; ENSG00000102755. [P17948-2]
DR   GeneID; 2321; -.
DR   KEGG; hsa:2321; -.
DR   UCSC; uc001usb.4; human. [P17948-1]
DR   CTD; 2321; -.
DR   DisGeNET; 2321; -.
DR   GeneCards; FLT1; -.
DR   H-InvDB; HIX0130593; -.
DR   HGNC; HGNC:3763; FLT1.
DR   HPA; CAB068189; -.
DR   HPA; CAB068190; -.
DR   HPA; HPA011740; -.
DR   HPA; HPA014290; -.
DR   MIM; 165070; gene.
DR   neXtProt; NX_P17948; -.
DR   OpenTargets; ENSG00000102755; -.
DR   PharmGKB; PA28180; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000037949; -.
DR   HOVERGEN; HBG053432; -.
DR   InParanoid; P17948; -.
DR   KO; K05096; -.
DR   OMA; ILTHIGH; -.
DR   OrthoDB; EOG091G01TL; -.
DR   PhylomeDB; P17948; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-194306; Neurophilin interactions with VEGF and VEGFR.
DR   Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization.
DR   SignaLink; P17948; -.
DR   SIGNOR; P17948; -.
DR   ChiTaRS; FLT1; human.
DR   EvolutionaryTrace; P17948; -.
DR   GeneWiki; FLT1; -.
DR   GenomeRNAi; 2321; -.
DR   PRO; PR:P17948; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; ENSG00000102755; -.
DR   CleanEx; HS_FLT1; -.
DR   ExpressionAtlas; P17948; baseline and differential.
DR   Genevisible; P17948; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:UniProtKB.
DR   GO; GO:0036332; F:placental growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0036326; F:VEGF-A-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0036327; F:VEGF-B-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0048598; P:embryonic morphogenesis; ISS:UniProtKB.
DR   GO; GO:0002548; P:monocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IMP:UniProtKB.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:ProtInc.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0036323; P:vascular endothelial growth factor receptor-1 signaling pathway; IDA:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 8.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   InterPro; IPR009135; VEGFR1_rcpt.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR01833; VEGFRECEPTR1.
DR   SMART; SM00409; IG; 7.
DR   SMART; SM00408; IGc2; 5.
DR   SMART; SM00406; IGv; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 8.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 6.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell membrane; Chemotaxis; Complete proteome; Cytoplasm;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; Endosome; Glycoprotein; Immunoglobulin domain; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     26       {ECO:0000269|PubMed:8248162}.
FT   CHAIN        27   1338       Vascular endothelial growth factor
FT                                receptor 1.
FT                                /FTId=PRO_0000016768.
FT   TOPO_DOM     27    758       Extracellular. {ECO:0000255}.
FT   TRANSMEM    759    780       Helical. {ECO:0000255}.
FT   TOPO_DOM    781   1338       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       32    123       Ig-like C2-type 1.
FT   DOMAIN      151    214       Ig-like C2-type 2.
FT   DOMAIN      230    327       Ig-like C2-type 3.
FT   DOMAIN      335    421       Ig-like C2-type 4.
FT   DOMAIN      428    553       Ig-like C2-type 5.
FT   DOMAIN      556    654       Ig-like C2-type 6.
FT   DOMAIN      661    747       Ig-like C2-type 7.
FT   DOMAIN      827   1158       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     833    841       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1022   1022       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     861    861       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        767    768       Cleavage; by PSEN1. {ECO:0000305}.
FT   MOD_RES     914    914       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:9722576}.
FT   MOD_RES    1053   1053       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1169   1169       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:9299537}.
FT   MOD_RES    1213   1213       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11513746,
FT                                ECO:0000269|PubMed:12796773,
FT                                ECO:0000269|PubMed:9299537,
FT                                ECO:0000269|PubMed:9600074,
FT                                ECO:0000269|PubMed:9722576}.
FT   MOD_RES    1242   1242       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MOD_RES    1309   1309       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12796773}.
FT   MOD_RES    1327   1327       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12796773,
FT                                ECO:0000269|PubMed:9722576}.
FT   MOD_RES    1333   1333       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:9722576}.
FT   CARBOHYD    100    100       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    164    164       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    196    196       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    251    251       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    323    323       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    402    402       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    417    417       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    474    474       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    547    547       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    597    597       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    620    620       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    625    625       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    666    666       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     53    107       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    158    207
FT   DISULFID    252    311       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    454    535       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    577    636       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    682    731       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ       1    995       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_041983.
FT   VAR_SEQ       1    875       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_041984.
FT   VAR_SEQ       1    782       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_041985.
FT   VAR_SEQ       1      7       MVSYWDT -> MNSDLLV (in isoform 8).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_047759.
FT   VAR_SEQ       8    984       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_047760.
FT   VAR_SEQ     518    541       MASTLVVADSRISGIYICIASNKV -> LPPANSSFMLPPT
FT                                SFSSNYFHFLP (in isoform 4).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041929.
FT   VAR_SEQ     542   1338       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041930.
FT   VAR_SEQ     657    687       DQEAPYLLRNLSDHTVAISSSTTLDCHANGV -> GEHCNK
FT                                KAVFSRISKFKSTRNDCTTQSNVKH (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8248162}.
FT                                /FTId=VSP_002955.
FT   VAR_SEQ     688   1338       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8248162}.
FT                                /FTId=VSP_002956.
FT   VAR_SEQ     706    733       GIILGPGSSTLFIERVTEEDEGVYHCKA -> ELYTSTSPS
FT                                SSSSSPLSSSSSSSSSSSS (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:18515749,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_041927.
FT   VAR_SEQ     734   1338       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:18515749,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_041928.
FT   VARIANT      60     60       K -> T (in dbSNP:rs56409818).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042045.
FT   VARIANT     128    128       I -> L (in dbSNP:rs35073261).
FT                                /FTId=VAR_049719.
FT   VARIANT     144    144       E -> K (in dbSNP:rs55974987).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042046.
FT   VARIANT     281    281       R -> Q (in dbSNP:rs55687105).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042047.
FT   VARIANT     422    422       L -> I (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042048.
FT   VARIANT     781    781       R -> Q (in a glioma low grade
FT                                oligodendroglioma sample; somatic
FT                                mutation; dbSNP:rs553261958).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042049.
FT   VARIANT     938    938       M -> V (in dbSNP:rs35549791).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042050.
FT   VARIANT     982    982       E -> A (in dbSNP:rs35832528).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042051.
FT   VARIANT    1061   1061       L -> V (in a bladder transitional cell
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042052.
FT   MUTAGEN     767    767       V->A: Abolishes proteolytic cleavage by
FT                                PSEN1. {ECO:0000269|PubMed:22016384}.
FT   MUTAGEN     861    861       K->M: Abolishes enzyme activity.
FT                                Abolishes interaction with PLCG.
FT                                {ECO:0000269|PubMed:9299537}.
FT   MUTAGEN     914    914       Y->F: Reduces phosphorylation at other
FT                                tyrosine residues.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MUTAGEN    1050   1050       N->D: Strongly increases kinase activity.
FT                                Increases activity in promoting
FT                                proliferation of endothelial cells.
FT                                {ECO:0000269|PubMed:16286478}.
FT   MUTAGEN    1169   1169       Y->F: Loss of phosphorylation site.
FT                                Abolishes interaction with PLCG.
FT                                {ECO:0000269|PubMed:9299537}.
FT   MUTAGEN    1213   1213       Y->F: Loss of phosphorylation site.
FT                                Abolishes interaction with PIK3R1.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MUTAGEN    1242   1242       Y->F: Loss of phosphorylation site.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MUTAGEN    1327   1327       Y->F: Loss of phosphorylation site.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MUTAGEN    1333   1333       Y->F: Loss of phosphorylation site.
FT                                Abolishes interaction with CBL.
FT                                {ECO:0000269|PubMed:15001553,
FT                                ECO:0000269|PubMed:9722576}.
FT   CONFLICT    490    490       F -> S (in Ref. 3; AAC16449).
FT                                {ECO:0000305}.
FT   CONFLICT    779    779       F -> L (in Ref. 1; CAA35946).
FT                                {ECO:0000305}.
FT   CONFLICT   1029   1029       L -> F (in Ref. 6; ABI53803/ABI53804).
FT                                {ECO:0000305}.
FT   TURN        130    132       {ECO:0000244|PDB:1QSV}.
FT   STRAND      135    137       {ECO:0000244|PDB:1FLT}.
FT   STRAND      140    142       {ECO:0000244|PDB:4CL7}.
FT   STRAND      144    148       {ECO:0000244|PDB:1FLT}.
FT   STRAND      150    152       {ECO:0000244|PDB:1QSZ}.
FT   STRAND      154    156       {ECO:0000244|PDB:1FLT}.
FT   STRAND      160    162       {ECO:0000244|PDB:5ABD}.
FT   HELIX       163    165       {ECO:0000244|PDB:1QSV}.
FT   STRAND      168    171       {ECO:0000244|PDB:1FLT}.
FT   TURN        172    174       {ECO:0000244|PDB:1FLT}.
FT   STRAND      175    177       {ECO:0000244|PDB:1FLT}.
FT   STRAND      181    187       {ECO:0000244|PDB:1FLT}.
FT   TURN        188    190       {ECO:0000244|PDB:1FLT}.
FT   STRAND      191    196       {ECO:0000244|PDB:1FLT}.
FT   HELIX       199    201       {ECO:0000244|PDB:1FLT}.
FT   STRAND      203    211       {ECO:0000244|PDB:1FLT}.
FT   STRAND      214    224       {ECO:0000244|PDB:1FLT}.
FT   HELIX       806    809       {ECO:0000244|PDB:3HNG}.
FT   HELIX       817    820       {ECO:0000244|PDB:3HNG}.
FT   HELIX       824    826       {ECO:0000244|PDB:3HNG}.
FT   STRAND      827    835       {ECO:0000244|PDB:3HNG}.
FT   STRAND      837    848       {ECO:0000244|PDB:3HNG}.
FT   HELIX       849    851       {ECO:0000244|PDB:3HNG}.
FT   STRAND      854    863       {ECO:0000244|PDB:3HNG}.
FT   HELIX       869    883       {ECO:0000244|PDB:3HNG}.
FT   STRAND      894    898       {ECO:0000244|PDB:3HNG}.
FT   STRAND      906    910       {ECO:0000244|PDB:3HNG}.
FT   HELIX       917    922       {ECO:0000244|PDB:3HNG}.
FT   HELIX       996   1014       {ECO:0000244|PDB:3HNG}.
FT   TURN       1015   1017       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1025   1027       {ECO:0000244|PDB:3HNG}.
FT   STRAND     1028   1030       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1032   1034       {ECO:0000244|PDB:3HNG}.
FT   STRAND     1036   1038       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1042   1044       {ECO:0000244|PDB:3HNG}.
FT   TURN       1047   1049       {ECO:0000244|PDB:3HNG}.
FT   STRAND     1053   1055       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1063   1065       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1068   1073       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1078   1093       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1107   1113       {ECO:0000244|PDB:3HNG}.
FT   TURN       1114   1116       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1127   1136       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1141   1143       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1147   1157       {ECO:0000244|PDB:3HNG}.
SQ   SEQUENCE   1338 AA;  150769 MW;  FF3381EEFAF0787C CRC64;
     MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK
     WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET
     ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD
     GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV
     KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK
     MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK
     AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA
     TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC
     DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK
     VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM
     HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRDQEA
     PYLLRNLSDH TVAISSSTTL DCHANGVPEP QITWFKNNHK IQQEPGIILG PGSSTLFIER
     VTEEDEGVYH CKATNQKGSV ESSAYLTVQG TSDKSNLELI TLTCTCVAAT LFWLLLTLFI
     RKMKRSSSEI KTDYLSIIMD PDEVPLDEQC ERLPYDASKW EFARERLKLG KSLGRGAFGK
     VVQASAFGIK KSPTCRTVAV KMLKEGATAS EYKALMTELK ILTHIGHHLN VVNLLGACTK
     QGGPLMVIVE YCKYGNLSNY LKSKRDLFFL NKDAALHMEP KKEKMEPGLE QGKKPRLDSV
     TSSESFASSG FQEDKSLSDV EEEEDSDGFY KEPITMEDLI SYSFQVARGM EFLSSRKCIH
     RDLAARNILL SENNVVKICD FGLARDIYKN PDYVRKGDTR LPLKWMAPES IFDKIYSTKS
     DVWSYGVLLW EIFSLGGSPY PGVQMDEDFC SRLREGMRMR APEYSTPEIY QIMLDCWHRD
     PKERPRFAEL VEKLGDLLQA NVQQDGKDYI PINAILTGNS GFTYSTPAFS EDFFKESISA
     PKFNSGSSDD VRYVNAFKFM SLERIKTFEE LLPNATSMFD DYQGDSSTLL ASPMLKRFTW
     TDSKPKASLK IDLRVTSKSK ESGLSDVSRP SFCHSSCGHV SEGKRRFTYD HAELERKIAC
     CSPPPDYNSV VLYSTPPI
//
